Results 181 to 190 of about 22,288 (223)
Some of the next articles are maybe not open access.
Ranibizumab for neovascular age-related macular degeneration
American Journal of Health-System Pharmacy, 2008The pharmacology, pharmacokinetics, clinical efficacy, safety, pharmacoeconomics, and place in therapy of ranibizumab are reviewed.Ranibizumab is the humanized fragment of the murine monoclonal antibody that binds all the active forms of the vascular endothelial growth factor, leading to the inhibition of the neovascular process underlying age-related ...
Luis Javier, Hernandez-Pastor +3 more
openaire +2 more sources
Management of neovascular age-related macular degeneration
Progress in Retinal and Eye Research, 2007Neovascular age-related macular degeneration (AMD) is becoming an increasing socio-medical problem as the proportion of the aged population is continuously increasing. However, new insights in the pathogenesis of the disease offer the opportunity to develop targeted therapies that attack the disease process more successfully than ever.
Ursula M, Schmidt-Erfurth +1 more
openaire +2 more sources
Neovascular Age-Related Macular Degeneration
Drugs, 2008Age-related macular degeneration (AMD) affects an estimated 14 million people worldwide, and is the leading cause of severe, irreversible vision loss in individuals over the age of 50 years in Western societies. Choroidal neovascularization (CNV), the hallmark of 'wet', 'exudative' or 'neovascular' AMD, is responsible for approximately 90% of cases of ...
Aimee V, Chappelow, Peter K, Kaiser
openaire +2 more sources
Neovascular Age-Related Macular Degeneration
Ophthalmology, 2013Age-related macular degeneration (AMD) progresses through early and intermediate to advanced stages, one of which is neovascular AMD (nAMD). A correct diagnosis of nAMD at an early stage is critical because unlike geographic atrophy, it can be treated with therapeutic agents.
Bianca S. Gerendas +3 more
openaire +2 more sources
Ranibizumab for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine, 2006Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration.In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular ...
Philip J, Rosenfeld +6 more
openaire +2 more sources
Review of Fibrosis in Neovascular Age-Related Macular Degeneration
American Journal of Ophthalmology, 2023To report the diagnosis and definitions, epidemiology, risk factors, and visual outcomes of fibrosis in neovascular age-related macular degeneration (nAMD).Systematic review and meta-analysis.The review was performed using the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
KAI XIONG CHEONG +2 more
openaire +2 more sources
Laser photocoagulation for neovascular age-related macular degeneration
Cochrane Database of Systematic Reviews, 2004Laser photocoagulation was the first treatment introduced to try to halt the progression of neovascular age-related macular degeneration (AMD), in which newly formed vessels or choroidal neovascularisation (CNV) grow under the macula leading to the occurrence of a scotoma or blind spot in the central visual field.The aim of this review was to examine ...
VIRGILI, GIANNI, A. Bini
openaire +3 more sources
Aflibercept for the treatment of neovascular age-related macular degeneration
Drugs of Today, 2012Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD.
E A, Verner-Cole, S J, Davis, A K, Lauer
openaire +2 more sources
Innovative therapies for neovascular age-related macular degeneration
Expert Opinion on Pharmacotherapy, 2019Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies.
Hasenin, Al-Khersan +3 more
openaire +2 more sources
Guidance for the treatment of neovascular age-related macular degeneration
Acta Ophthalmologica Scandinavica, 2007Neovascular age-related macular degeneration is becoming an increasing socio-medical problem as the proportion of the aged population is continuously increasing. However, new insights in the pathogenesis of the disease offer the opportunity to develop targeted therapies that attack the disease process more successfully than ever.
Schmidt Erfurth UM +9 more
openaire +2 more sources